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Oral squamous cell carcinoma (OSCC) frequently invades mandibular bone, and outcomes for treatment with surgical resection
are typically poor, ultimately resulting in death.Holarrhena antidysenterica L. (Apocynaceae), distributed throughout Sri Lanka and
India, has been used as a folk remedy to treat various diseases. Treatment with methanol extract ofH. antidysenterica bark (HABE)
inhibited cell viability and BrdU incorporation and induced apoptotic cell death in Ca9-22 gingival and HSC-3 tongue SCC cells.
Flow cytometric analysis indicated that HABE treatment preferentially induces apoptotic cell death via increasing the sub-G1 peak
in Ca9-22 cells and cell cycle arrest at the G1 phase in HSC-3 cells. HABE treatment in the presence of zVAD-fmk, a pan-caspase
inhibitor, rescued cell viabilities in both OSCC cell lines. The ratio of Bax to Bcl-2 increased with reductions in the Bcl-2 protein
expression, and the activation of caspase 3 and subsequent cleavage of PARPwas detected inHABE-treated Ca9-22 andHSC-3 cells.
Furthermore, HABE treatment at noncytotoxic concentrations inhibited osteoclast formation in RANKL-stimulated bone marrow
macrophages. Taken together, HABE possesses the inhibitory activity on the growth ofOSCC cells and antiosteoclastogenic activity.
Therefore, HABE may be a promising alternative and complementary agent for preventing and treating OSCC.
1. Introduction
Oral squamous cell carcinoma (OSCC) is themost frequently
diagnosed malignant cancer in the head and neck region,
accounting for approximately 95% of oral cancers [1]. The
annual incidence of OSCC ranges from 400,000 to 500,000
new cases worldwide and has varied from less than 2 per
100,000 in the Middle East to 10 per 100,000 in USA and
over 20 per 100,000 people in India [2, 3]. Southeast Asia,
including India, Pakistan, Bangladesh, and Sri Lanka, has
a high prevalence of OSCC due to cultural practices, such
as betel-quid chewing and distinct patterns of tobacco and
alcohol use. Thus, OSCC is a public health problem with a
high treatment cost as well as a high mortality [4]. Tongue
carcinoma is the leading site for OSCC in India, and the
buccal mucosa and gingiva are the next most common sites
in Southeast Asia [5]. In particular, gingival squamous cell
carcinomas frequently invade mandibular bone and should
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be treated by surgical resection [6]. However, the treatment
results are typically poor; nearly 70% of cases recur at the
primary lesion site and ultimately result in death [7]. Bone-
targeting agents, such as nitrogen-containing bisphospho-
nates, are also applied to OSCC patients to block cancer-
related bone destruction.However, long-term administration
of aminobisphosphonates causes severe osteonecrosis of the
jaw, characterized by exposure of mandibular or maxillary
bone [8]. Therefore, novel agents with anticancer and anti-
bone resorptive activities are required for improving survival
rate and quality of life in OSCC patients.
Phytochemicals and extracts derived from medicinal
plants have been noted as promising cancer-preventive agents
against several cancers because of their low toxicity and the
accumulating data supporting their beneficial health effects
[9]. Holarrhena antidysenterica L. (Apocynaceae), which is
distributed throughout Sri Lanka and India up to an altitude
of 3,500 ft, has been used as a folk remedy for treating various
diseases, including diarrhea, stomach pain, and dysentery, in
India [10]. Seed extract ofH. antidysenterica has antidiabetic,
antihyperglycemic, and antihyperlipidemic activities [11].The
methanol extract of H. antidysenterica leaves, which has a
high level of total phenolic content, scavenges reactive oxygen
species (ROS) that otherwise participate in every step of
carcinogenesis by causing intrinsic oxidative stress [12, 13].
The ethanol extract of H. antidysenterica leaves has cytotoxic
activity against OVCAR-5 (ovary), HT-29 (colon), SK-N-MC
(neuroblastoma), HEP-2 (liver), COLO-205 (colon), NIH-
OVCAR-3 (ovary), and A-549 (lung) cancer cell lines [14].
However, the effect of H. antidysenterica bark extract on
OSCC cell growth and bone invasion has not previously been
studied.
In this study, we evaluated the preventive and therapeutic
potential ofH. antidysenterica stem and bark extract (HABE)
by investigating its antiproliferative and apoptosis-inducing
activity in Ca9-22 gingival SCC and HSC-3 tongue SCC cells
as well as its antiosteoclastogenic activity in bone marrow
macrophages, which act as osteoclast precursors.
2. Materials and Methods
2.1.Materials. Fetal bovine serum (FBS),Dulbecco’smodified
Eagle’s Medium (DMEM), 0.25% trypsin-EDTA, and
antibiotic-antimycotic mixture were purchased from Gibco
BRL (Rockville, MD, USA). Phosphate-buffered saline (PBS)
was purchased from Bio-Solution (Suwon, Korea). 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT)
and dimethyl sulfoxide (DMSO) were purchased from
Sigma-Aldrich (St. Louis, MO, USA). zVAD-fmk was
purchased from Enzo Life Sciences (Farmingdale, NY,
USA). Bicinchoninic acid (BCA) protein assay reagent and
enhanced chemiluminescence (ECL) kits were obtained
from Pierce (Rockford, IL, USA) and Amersham (GE
Healthcare, UK), respectively. Anti-human Bcl-2, procaspase
3, and PARP antibodies were obtained from Cell Signaling
Technology (Beverly, MA, USA). Anti-human Bax and
GAPDH antibodies and horseradish peroxidase-conjugated
anti-rabbit and anti-mouse second antibodies were
purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). All reagents used in this study were analytical
grade.
2.2. Preparation of Methanol Extract of H. antidysenterica
Bark (HABE). Dried bark of H. antidysenterica was pur-
chased from an herbal drug store at Kurunegala in the North-
Western Province of Sri Lanka.The commercial plant sample
was authenticated by a chemotaxonomic procedure and by
comparison with an authentic voucher specimen (# 4539)
found in the National Herbarium, Peradeniya, Sri Lanka.
The dried bark was pulverized and the powder (60 g) was
extracted with methanol (400ml) in a Soxhlet apparatus
for 12 h after defatting with hexane (400ml, 12 h, Soxhlet).
The extract was filtered under vacuum through a Whatman
No. 1 filter paper and evaporated to dryness under reduced
pressure using a Rotavapor (Heidolph Laborta 4000). HABE
(2.0 g, 3.3%) was stored at −20∘C.HABE for next experiments
was dissolved with DMSO and diluted with serum-free
media.
2.3. Cell Culture. Ca9-22 gingival and HSC-3 tongue SCC
cells were cultured in DMEM supplemented with 10%
FBS and 1% antibiotic-antimycotic mixture at 37∘C in a
humidified atmosphere with 5% CO
2
. Murine bone marrow
macrophages (BMMs) were isolated from the tibiae of 4-
week-old ICR mice as previously described [15], and they
were cultured with 𝛼-MEM containing M-CSF (30 ng/ml),
10% FBS, and 1% antibiotic-antimycotic mixture in a humid-
ified atmosphere with 5% CO
2
at 37∘C.
2.4. Cell Viability and Proliferation Assay. Ca9-22 and HSC-
3 cells (1 × 103 cells/well) were seeded in 96-well plates and
cultured inDMEMcontaining 10%FBS for 24 h.The attached
cells were incubated with the indicated concentrations of
HABE in serum-free media for 24 and 72 h. Control cells
were exposed to media with 0.1% DMSO. Cell viability was
assessed using anMTTassay.The cells were further incubated
at 37∘C for 4 h with MTT solution (0.5mg/ml, 20𝜇l/well).
DMSO (200𝜇l/well) was added to each well to dissolve
formazan. The absorbance was measured at 570 nm using a
microplate reader (Bio-Rad Lab, Hercules, CA, USA). The
amount of the newly synthesized DNA was measured using
a 5-bromo-2󸀠-deoxyuridine (BrdU) cell proliferation assay
kit according to the manufacturer’s protocol (Roche Applied
Science, Penzberg, Germany).
2.5. Cell Cycle Distribution Analysis. Ca9-22 or HSC-3 cells
(5 × 105 cells) were seeded in six-well culture plates and
incubated overnight. The cells were treated with different
concentrations of HABE in serum-free media for 24 h. The
cells were harvested with trypsin-EDTA, washed with PBS,
and fixed with ice-cold 70% ethanol overnight at 4∘C. The
cells werewashedwith PBS again and incubated in propidium
iodide solution containing 1mg/ml RNase A, 0.1% Triton-X,
and 0.1mg/ml propidium iodide at room temperature in the
dark for 30min. The DNA content was then detected using a
flow cytometer (BD Bioscience, Franklin Lakes, NJ, USA).
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2.6. Apoptosis and Necrosis Assay. Ca9-22 and HSC-3 cells (1
× 103 cells/well) were seeded in 96-well plates with DMEM
containing 10% FBS for 24 h. The attached cells were treated
with the various concentrations of HABE in serum-free
media for 24 h. A cell death detection ELISA kit (Roche
Diagnostics, Mannheim, Germany) was used to assess apop-
totic and necrotic cell death according to the manufacturer’s
instruction.The absorbance was measured at 405 nm using a
microplate reader.
2.7. Western Blot Analysis. Human oral cancer Ca9-22 (5 ×
105 cells) and HSC-3 (1 × 106 cells) cells were seeded in
100mm culture dishes with DMEM containing 10% FBS for
24 h at 37∘C in a humidified atmosphere with 5% CO
2
. The
attached cells were treated with the various concentrations of
HABE in serum-free DMEM for 24 h. The cells were lysed
with RIPA buffer (Cell Signaling Technology) containing
1mM phenylmethylsulfonyl fluoride and protease inhibitor
cocktail (Roche, Mannheim, Germany). The cell lysates were
centrifuged at 22,000×g for 15min at 4∘C, and the super-
natants were quantitated using BCA protein assay reagents
(Pierce, Rockford, IL). Cell extracts were separated using 12%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
and transferred to a polyvinylidene difluoride membrane
(Millipore, Danvers, MA). The membrane was blocked with
10% skimmilk and incubatedwith primary antibodies against
specific target proteins in 3% skim milk, which was followed
by incubation with horseradish peroxidase-conjugated sec-
ondary antibodies for 1 h. The target proteins were detected
using an ECL kit (Amersham, Piscataway, NJ) according
to the manufacturer’s protocol. Densitometric analysis was
performed using Image J software.
2.8. Osteoclast Formation. BMMs (5 × 104 cells/well) were
seeded in a 96-well plate and incubatedwith𝛼-MEMcontain-
ing 10% FBS, M-CSF (30 ng/ml), sRANKL (100 ng/ml), and
different HABE concentrations for 5 days. Tartrate-resistant
acid phosphatase- (TRAP-) positive multinucleated osteo-
clasts with more than three nuclei were counted under light
microscopy (×100 magnification) as previously described
[15].
2.9. Statistical Analysis. Thedata are expressed as themeans±
standard error (SE). One-way analysis of variance (ANOVA)
was performed for statistical analysis, and Student’s 𝑡-test was
used to evaluate the differences between each group. 𝑃 values
less than 0.05 were considered statistically significant.
3. Results and Discussion
Oxidative stress induced by ROS is closely related to cancer
development as a result of DNA damage and the subsequent
mutations [16]. ROS enhances bone resorption as it serves
as second messengers in osteoclastogenesis-related signaling
pathways [17, 18]. Thus, natural products with antioxidant
activity can be promising agents for controlling both cancer
growth and the related bone destruction. On the other hand,
several studies have demonstrated that polyphenols in the
presence of metal ions can induce DNA degradation and
consequently result in cell death by acting as prooxidants
[19, 20].
We first assessed the anticancer activity of HABE on
OSCC by investigating its antiproliferative and apoptosis-
inducing activity in two OSCC cell lines. Treatment with
HABE for 24 h inhibited the viabilities of Ca9-22 gingival
and HSC-3 tongue SCC cells by 35% and 26%, respectively,
at 50𝜇g/ml and 58% and 51%, respectively, at 100 𝜇g/ml
(IC
50
= 83 𝜇M for Ca9.22 and 98 𝜇M for HSC-3). The cell
viabilities were inhibited by 77% and 67%, respectively, after
72 h of treatment at 20𝜇g/ml (IC
50
= 1.6 𝜇M for Ca9.22 and
1.7 𝜇M for HSC-3) (Figure 1(a)). Abnormally promoted cell
proliferation and dysregulated apoptosis contribute to the
unlimited proliferative potential of cancer [21].We confirmed
that HABE reduced the proliferation of OSCC cells by
measuring the reduced BrdU incorporation in two HABE-
treated OSCC cell lines. Treatment with 50𝜇g/ml HABE for
24 h reduced the proliferation by 28% inCa9-22 cells and 43%
in HSC-3 cells. Treatment with 100𝜇g/ml extract inhibited
the proliferation of these cells by more than 90% in both
OSCC cell lines (Figure 1(b)). Apoptotic and necrotic cell
death were analyzed by measuring the histone-associated
DNA fragments in cell lysates and culturemedia, respectively,
from Ca9-22 and HSC-3 cells that were treated with HABE.
Apoptotic cell deathwas increased 7.1- and 12.5-fold inCa9-22
cells treated with 20𝜇g/ml and 50𝜇g/ml HABE, respectively,
and 2.6- and 6.6-fold in HSC-3 cells treated with 50𝜇g/ml
and 100 𝜇g/ml HABE, respectively. Lower levels of necrotic
cell death were observed compared to apoptotic cell death in
Ca9-22 cells that were treatedwithmore than 50𝜇g/mlHABE
and in HSC-3 cells that were treated with 100𝜇g/ml HABE
(Figure 1(c)). These results indicate that HABE treatment can
inhibit the growth of OSCC cells primarily by blocking cell
proliferation and inducing apoptosis in Ca9-22 and HSC-3
cells.
To further verify the growth inhibitory activity of HABE,
we examined whether this extract could arrest the cell cycle
in Ca9-22 and HSC-3 cells. Flow cytometric analysis showed
that the sub-G1 peak was noticeably increased in HABE-
treated Ca9-22 cells (Figure 2(a)) and cell populations at the
G1 phase was dose-dependently enhanced in HABE-treated
HSC-3 cells (Figure 2(b)). Therefore, treatment with this
extract may strongly induce apoptotic cell death in Ca9-22
cells. In HSC-3 cells, HABE treatment may trigger apoptotic
cell death via cell cycle arrest at the G1 phase.
We studied the molecular mechanism by which HABE
could stimulate apoptotic cell death. The apoptosis sig-
naling pathway is transduced through the intrinsic path-
way (mitochondrial-dependent) or extrinsic (death receptor-
dependent) pathway. In particular, the intrinsic pathway
via the Bcl-2 family members, including the proapoptotic
proteins (e.g., Bax, Bad, and Bak) and antiapoptotic proteins
(e.g., Bcl-2 and Bcl-xL), play a pivotal role in transduc-
ing apoptotic signals [21, 22]. Among them, the ratio of
proapoptotic Bax to antiapoptotic Bcl-2 can be a checkpoint
for assessing apoptosis and is positively correlated with
apoptosis induction [23]. Mitochondrial malfunction, which
is expedited by pro- and antiapoptotic Bcl-2 family proteins,
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Figure 1: The inhibitory effect of HABE on the growth of oral cancer cells. Ca9-22 and HSC-3 cells (1 × 103 cells/well) were cultured in
serum-free media with the indicated HABE concentrations. (a) After 24 or 72 h of treatment with HABE, the cell viability was determined
using an MTT assay. (b) After 24 h of treatment, the amount of newly synthesized DNA was evaluated using a BrdU incorporation assay,
and (c) apoptosis and necrosis were assessed with a Cell Death Detection ELISA kit. Data are expressed as the mean ± SE. ∗𝑃 < 0.05 and
∗∗
𝑃 < 0.001 versus vehicle-treated cells.
Evidence-Based Complementary and Alternative Medicine 5
200
Ca
9-
22
50
0 g/ml
20 g/ml
50 g/ml
∗ ∗
∗
∗∗
∗∗ ∗∗
0
10
20
30
40
50
60
70
80
%
 o
f c
el
l n
um
be
rs
G1 S G2/MSubG1
HABE (g/ml)
800
600
400
200
0
C
ou
nt
Comp-PE-A:: PE-A
2
5
0
K
2
0
0
K
1
5
0
K
1
0
0
K
5
0
K0
Comp-PE-A:: PE-A
2
5
0
K
2
0
0
K
1
5
0
K
1
0
0
K
5
0
K0
Comp-PE-A:: PE-A
2
5
0
K
2
0
0
K
1
5
0
K
1
0
0
K
5
0
K0
0
C
ou
nt
C
ou
nt
300
200
100
250
200
150
100
50
0
(a)
H
SC
-3
0 g/ml
20 g/ml
50 g/ml
∗ ∗
∗
∗
0
10
20
30
40
50
60
70
80
%
 o
f c
el
l n
um
be
rs
S G2/MG1
200 50
HABE (g/ml)
0 0
C
ou
nt
800
600
400
200
800
1000
600
400
200
C
ou
nt
C
ou
nt
Comp-PE-A:: PE-A
2
5
0
K
2
0
0
K
1
5
0
K
1
0
0
K
5
0
K0
Comp-PE-A:: PE-A
2
5
0
K
2
0
0
K
1
5
0
K
1
0
0
K
5
0
K0
Comp-PE-A:: PE-A
2
5
0
K
2
0
0
K
1
5
0
K
1
0
0
K
5
0
K0
1200
900
600
300
0
(b)
Figure 2: Cell cycle distribution inHABE-treated OSCC cells. (a) Ca9-22 or (b) HSC-3 cells were treated with different HABE concentrations
in serum-free media for 24 h. The cells fixed with ice-cold 70% ethanol were incubated in propidium iodide solution for 30min as described
in the Materials and Methods section. DNA content was detected using a flow cytometer. Data are expressed as the mean ± SE. ∗𝑃 < 0.05
and ∗∗𝑃 < 0.001 versus vehicle-treated cells.
causes cytochrome 𝑐 release.The released cytochrome 𝑐 forms
an apoptosome with caspase 9 and Apaf-1 and triggers the
caspase cascade, including caspase 3 activation [24]. The
activated caspase 3 cleaves poly(ADP-ribose) polymerase
(PARP), which is associated with DNA damage repair [21, 25,
26]. In our study, HABE treatment in the presence of zVAD-
fmk, a pan-caspase inhibitor, rescued the cell viabilities in
both OSCC cell lines, suggesting that caspase activation is
required for HABE-induced apoptosis (Figure 3(a)). In turn,
we confirmed that treatment with HABE elevated the Bax to
Bcl-2 ratio by reducing Bcl-2 protein expression and resulted
in the caspase 3 activation and PARP cleavage in Ca9-22 and
HSC-3 cells (Figure 3(b)). These results indicate that HABE
extract induces apoptosis through the intrinsic pathway in
Ca9-22 and HSC-3 cells. Low Bcl-2 level may affect the
responsiveness of Ca9.22 cells on HABE treatment.
Bone resorption occurring in the maxillary or mandibu-
lar bone of OSCC patients is mediated by osteoclasts rather
than by the carcinoma itself. OSCC cell-derived factors
promote the production of RANKL in osteoblastic/stromal
cells, and this RANKL promotes the formation of mature
osteoclasts from osteoclast precursors. Bone resorption by
mature osteoclasts releases growth factors from mineralized
matrix and consequently multiplies tumor growth and the
production of osteolytic factors [27]. We examined the
antiosteoclastogenic activity of HABE in RANKL-stimulated
BMMs. Treatment with HABE inhibited the viability of
BMMs by 40% at 20 𝜇g/ml (Figure 4(a)) and inhibited
RANKL-induced osteoclast formation by 37% at 5 𝜇g/ml and
76% at 10 𝜇g/ml (IC
50
= 6.1 𝜇M) (Figure 4(b)).
4. Conclusion
HABE inhibited the proliferation by arresting cell cycle at the
G1 phase and promoted apoptosis via intrinsic (mitochon-
drial) pathway in OSCC cells. In addition, HABE blocked
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Figure 3: Induction of apoptotic cell death in HABE-treated oral cancer cells. (a) Ca9-22 andHSC-3 cells (1 × 103 cells/well) were treated with
the indicated HABE concentrations in the presence of a pan-caspase inhibitor, zVAD-fmk (10 𝜇M), for 24 h. Cell viability was assessed using
anMTT assay. (b) Ca9-22 and HSC-3 cells were treated with the indicated HABE concentrations for 24 h.The levels of Bax, Bcl-2, procaspase
3, and full-length and cleaved PARP were detected by western blot analysis with specific antibodies. The images are representatives of three
independent experiments. The ratio of Bax to Bcl-2 was determined after normalization with the GAPDH intensity by densitometry. Data are
expressed as the mean ± SE. ∗𝑃 < 0.05 and ∗∗𝑃 < 0.001 versus vehicle alone-treated cells; #𝑃 < 0.001 versus the cells treated with vehicle and
zVAD-fmk.
RANKL-induced osteoclastogenesis at noncytotoxic concen-
trations. A clinical pharmacology study reported that 70% of
clinical symptoms were improved in the individuals given 4 g
of H. antidysenterica stem bark extract/day [11]. Therefore,
HABE may be a safe anticancer agent against OSCC growth
and OSCC-mediated bone resorption. Further studies are
required to identify major active components of HABE and
to determine their in vivo activities.
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Figure 4:The inhibitory effect of HABE on RANKL-induced osteoclastogenesis. (a) BMMs (5 × 104 cells/well) were treated with the indicated
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